SAMS Announces Addition of API Innovation Center (APIIC) To Coalition
WASHINGTON D.C., July 24, 2024 — Today, Securing America’s Medicines and Supply (SAMS) formally announced the addition of the API Innovation Center (APIIC) to the coalition. APIIC joins SAMS’s growing membership to advocate for policy recommendations to address ongoing chronic drug shortages.
APIIC brings to the coalition its wealth of experience in enabling the delivery of market-competitive commercial supply of U.S.-made active pharmaceutical ingredients (APIs) to address critical needs in the healthcare supply chain.
“We are excited to welcome APIIC to SAMS,” said David Sanders, Executive Director of SAMS and Vice President of Government Affairs & Policy at Coherus Biosciences.
“Addressing drug shortages and supply chain resiliency is a multi-faceted effort, and needs the leadership of key stakeholders, especially those actively involved in the domestic production of essential drugs. By welcoming APIIC into our coalition, we are strengthening our collective voice and acknowledging critical – and practical – solutions. Tony and his team, and their approach, highlight the urgent need for policy solutions, industry input, and the resilience and reliability of our pharmaceutical supply chain.”
Tony Sardella, Chair and Founder of APIIC, added, “We are proud to join SAMS and its members in strengthening the availability of high-quality, generic medications for patients, healthcare systems, and pharmacies. We look forward to informing key stakeholders on the critical issues related to reshoring essential medications to build our nation’s health security.”
SAMS membership and advisors are dedicated to working with Congressional stakeholders and the Administration to implement broad legislative solutions to improve and sustain the U.S. medical supply chain for pharmaceuticals and devices.
###
About the API Innovation Center:
The API Innovation Center (APIIC) is a 501(c)(3) nonprofit public benefit organization headquartered in St. Louis, Missouri, dedicated to revolutionizing pharmaceutical development through cutting-edge research in chemical and semi-synthetic research. By developing and leveraging advanced manufacturing technologies, APIIC aims to create sustainable and efficient routes for producing vital pharmaceuticals in the U.S. Through investments in and collaboration along the supply chain, APIIC’s model contracts leading U.S.-based specialists within their pharmaceutical ecosystem to develop and manufacture Active Pharmaceutical Ingredients (APIs), ensuring high-quality domestically produced pharmaceuticals. APIIC is committed to expanding access to critical medications through strategic partnerships to commercialize market-competitive supplies of finished drug products. Their mission is to ensure every hospital, pharmacy, and American has access to domestically produced critical medication to support national health security. APIIC is supported by the state of Missouri through the Advanced Manufacturing Resiliency Grant awarded by the Missouri Technology Corporation. To learn more, visit: apicenter.org.